On Jul. 31, 2020, Sanofi and GSK announced advanced discussions, with the European Commission for the supply of up to 300 million doses of a COVID-19 vaccine. The vaccine candidate is based on the recombinant protein-based technology used by Sanofi to produce an influenza vaccine, and GSK’s established adjuvant technology.

The doses would be manufactured in European countries including France, Belgium, Germany and Italy.